BTR Capital Management Inc. lessened its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,822 shares of the medical research company’s stock after selling 65 shares during the period. BTR Capital Management Inc.’s holdings in Amgen were worth $439,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the business. IFP Advisors Inc boosted its position in shares of Amgen by 17.9% during the fourth quarter. IFP Advisors Inc now owns 4,572 shares of the medical research company’s stock worth $1,097,000 after purchasing an additional 695 shares in the last quarter. Strategic Family Wealth Counselors L.L.C. bought a new stake in shares of Amgen during the 4th quarter worth approximately $214,000. Comprehensive Portfolio Management LLC lifted its holdings in shares of Amgen by 2.3% during the 4th quarter. Comprehensive Portfolio Management LLC now owns 3,784 shares of the medical research company’s stock worth $912,000 after acquiring an additional 86 shares during the period. Arlington Partners LLC lifted its holdings in shares of Amgen by 25.6% during the 4th quarter. Arlington Partners LLC now owns 490 shares of the medical research company’s stock worth $118,000 after acquiring an additional 100 shares during the period. Finally, Stordahl Capital Management Inc. bought a new stake in shares of Amgen during the 4th quarter worth approximately $203,000. 76.58% of the stock is owned by hedge funds and other institutional investors.
In other Amgen news, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $215.45, for a total value of $91,566.25. Following the completion of the transaction, the director now directly owns 5,413 shares in the company, valued at approximately $1,166,230.85. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 9,000 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $230.54, for a total transaction of $2,074,860.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,162 shares of company stock valued at $4,214,030. Corporate insiders own 0.25% of the company’s stock.
NASDAQ AMGN traded down $0.01 on Friday, hitting $240.49. The company’s stock had a trading volume of 492,919 shares, compared to its average volume of 1,906,640. The company has a quick ratio of 2.59, a current ratio of 2.89 and a debt-to-equity ratio of 2.54. Amgen, Inc. has a 1-year low of $166.30 and a 1-year high of $244.99. The company’s 50-day moving average is $238.44 and its 200 day moving average is $209.08. The firm has a market cap of $142.60 billion, a PE ratio of 16.70, a PEG ratio of 2.08 and a beta of 1.11.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, October 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.53 by $0.13. Amgen had a net margin of 34.48% and a return on equity of 80.26%. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.63 billion. During the same period in the prior year, the company posted $3.69 EPS. The company’s revenue was down 2.8% on a year-over-year basis. On average, equities analysts expect that Amgen, Inc. will post 14.58 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 14th will be given a $1.60 dividend. This is a boost from Amgen’s previous quarterly dividend of $1.45. This represents a $6.40 annualized dividend and a yield of 2.66%. The ex-dividend date of this dividend is Thursday, February 13th. Amgen’s dividend payout ratio is 40.28%.
Several brokerages recently commented on AMGN. Goldman Sachs Group set a $243.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Monday, September 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $255.00 price objective on shares of Amgen in a research note on Tuesday. Leerink Swann increased their price objective on shares of Amgen from $189.00 to $205.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Morgan Stanley dropped their price objective on shares of Amgen from $280.00 to $277.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Bank of America began coverage on shares of Amgen in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $215.00 price objective for the company. Eleven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Amgen presently has a consensus rating of “Buy” and a consensus target price of $235.22.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Story: S&P 500 Index
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.